Phase 1/2 clinical studies showed the safety of applying low-dose IL-2 in the treatment of patients with chronic graft-versus-host disease (GVHD) 25, hepatitis C virus (HCV)-induced vasculitis 26, and type 1 diabetes (T1D) 27. The gene discussed is IL2; the disease is type 1 diabetes mellitus.